Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 , an orally available small molecule inhibitor of phosphoinositide-3-kinase and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, … View full post on NewsBlaze.com Current News – California

Popularity: 5% [?]

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral … View full post on NewsBlaze.com Current News – California

Popularity: 2% [?]

Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR trial of picoplatin in the second-line treatment of small cell lung … View full post on NewsBlaze.com Current News – California

Popularity: 5% [?]

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the … View full post on NewsBlaze.com Current News – California

Popularity: 5% [?]